Navigation Links
MitoAction Develops On-Line Resource for Mitochondrial Disease Care Providers
Date:7/23/2008

Online Clinicians Guide to Mitochondrial Disease Now Available, sponsored by Edison Pharma

Boston (PRWEB) July 23, 2008 -- MitoAction.org announces today the completion of the Clinicians Symptom Guide to MITO Management, a comprehensive online resource designed to assist primary care providers in the care and symptom management of patients affected by mitochondrial disease. The Clinicians Symptom Guide to MITO Management fills a gap in healthcare libraries which to date have offered no practical overview for patient management. MitoAction fulfills their mission to support, educate and advocate for the mitochondrial disease patient community through development of the Clinicians Symptom Guide to MITO Management.

Mitochondrial disease is an energy metabolism disorder found in approximately one in 4,000 individuals in the U.S. The disease affects children as well as adults, and commonly manifests with neuromuscular symptoms such as stroke, muscle pain, extreme fatigue, and organ failure. There are no FDA approved drugs for mitochondrial disease. Symptoms vary widely from patient to patient; in many cases, the disease is inherited.

Written in collaboration with Margaret Klehm, CPNP and Mark Korson MD of the Floating Hospital for Children at Tufts Medical Center, the Clinicians Symptom Guide to MITO Management is the only resource of its kind. The Clinicians Symptom Guide to MITO Management is now freely available to the public online at http://www.mitoaction.org/. In light of the recent attention to the autism-mitochondrial disease connection, the need for this practical and comprehensive resource is apparent. This information needs to be accessed by the public and medical providers in order to improve quality of life and care for the person suffering from 'Mito,' says Cristy Balcells, Executive Director of MitoAction.

Dr. Korson is a leading clinician in the field of mitochondrial medicine, and has treated over 1,000 mitochondrial disease patients. This community of patients is terribly under-recognized and underserved. There are simply not enough clinicians aware of Mito, or who will play an active role in the care of these patients. As a result, it is too often the patient or the family member who becomes the de facto primary care provider.

MitoAction anticipates that the Clinicians Symptom Guide to MITO Management will improve baseline care and understanding of the complexities of mitochondrial disease, as well as educate pediatricians, primary care physicians, and home health nurses about managing the disease.

Edison Pharma (http://edisonpharma.com) is the dedicated sponsor for the project. We are honored to support the development of this important resource for clinicians and care-providers, stated Guy Miller, MD, PhD, CEO of Edison. This is a wonderful initiative that will go a long way to standardizing care for patients with mitochondrial disorders. MitoAction is grateful for Edisons support for this project to improve patient care for those affected by mitochondrial disease.

Further questions may be directed to Cristy Balcells, RN MSN Executive Director at 423-914-8322 or director @ mitoaction.org

SOURCE MitoAction

###

Read the full story at http://www.prweb.com/releases/2008/07/prweb1134624.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. HighPoint Solutions Develops Novel Incentive Compensation Plan for New Benign Prostatic Hyperplasia (BPH) Product
2. URAC Develops New Case Management Patient Satisfaction Tool, Invites Public Input On Voluntary Survey Instrument
3. China Sky One Medical, Inc. Successfully Develops Semi-Quantitative Automatic Inspection Device for Diagnostic Kits
4. SellingLTC.com Develops simplifyingLTC
5. Medical Records Institute (MRI) Develops Initiative for EMRs Supporting Medicolegal Requirements
6. Psychologist develops post-operative care for heart patients in Bermuda
7. Omron Healthcare Develops Solar-Powered Digital Blood Pressure Monitors
8. MIT develops thin-film micro pharmacy
9. Capsulated Systems, Inc. Develops Long Term Local Anesthetic
10. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
11. Silverchair Learning Systems Updates and Develops New Courses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne ... signature product of her research center at Bio-Logic Aqua Research® Water Life Science®, ... the greatest number of sufferers of blindness. “We think that Nature’s Tears® EyeMist® ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... may give insight into why concussion rates are on the rise, say researchers ... Annual Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... enterprise-grade IT operations analytics and application performance monitoring (APM) solutions, has expanded ... healthcare services providers. , According to Peter Ohrenberger, sales director at Nastel, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Team Type 1 Foundation, a ... for everyone affected by diabetes, is teaming up with a Microsoft Corp. employee-led hackathon ... off on July 24th. , “Team Type 1’s mission overlaps seamlessly with Microsoft’s ...
(Date:7/20/2017)... ... July 20, 2017 , ... Using CDRH’s Medical Device ... — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata          , Device makers ... It’s known as the “CY2016 Annual FDA Medical Device Quality System Data” report. ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... division of Diplomat Specialty Infusion Group, is celebrating a decade of empowering ... celebrate its anniversary, ThriveRx recently launched a redesigned website at thriverx.diplomat.is ... to create the best user experience for consumers and health care professionals. ... Diplomat Pharmacy ... "We,ve made several great strides throughout the past 10 years," ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... a clinical-stage pharmaceutical company focused on the development of oral ... from the Israel Securities Authority to dual-list its common stock ... will commence trading on the TASE on July 12, 2017 ... of the Company, it is expected that Oramed will be ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
Breaking Medicine Technology: